LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Accueil・Liste d'Actions・Anika Therapeutics Inc

Anika Therapeutics Inc

Fermé

SecteurSoins de santé

14.85 -0.54

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.76

Max

14.88

Chiffres clés
By Trading Economics
Revenu	-5.3M -5.1M
Ventes	-1M 30M
BPA	0.27
Marge bénéficiaire	-17.074
Employés	235
EBITDA	-6.3M -4.1M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+17.61% upside

Dividendes
By Dow Jones
Prochains Résultats	29 juil. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-30M 199M
Ouverture précédente	15.39
Clôture précédente	14.85

Sentiment de l'Actualité

By Acuity

50%

159 / 345 Classement par Healthcare

Anika Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 mai 2026, 08:24 UTC

Principaux Mouvements du Marché

Acquisitions, Fusions, Rachats

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mai 2026, 21:22 UTC

Résultats

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mai 2026, 20:50 UTC

Market Talk

Résultats

Basic Materials Roundup: Market Talk

25 mai 2026, 16:20 UTC

Market Talk

Résultats

Basic Materials Roundup: Market Talk

25 mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mai 2026, 12:56 UTC

Market Talk

Résultats

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mai 2026, 12:10 UTC

Market Talk

Acquisitions, Fusions, Rachats

Delivery Hero's Assets Look Strategic -- Market Talk

25 mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mai 2026, 10:05 UTC

Résultats

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mai 2026, 10:04 UTC

Résultats

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mai 2026, 10:03 UTC

Résultats

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mai 2026, 10:02 UTC

Résultats

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mai 2026, 10:01 UTC

Résultats

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mai 2026, 10:00 UTC

Résultats

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mai 2026, 09:56 UTC

Résultats

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mai 2026, 09:56 UTC

Résultats

Tenaga Nasional 1Q EPS MYR0.1883

25 mai 2026, 09:56 UTC

Résultats

Tenaga Nasional 1Q Rev MYR17.1B

25 mai 2026, 09:56 UTC

Résultats

Tenaga Nasional 1Q Net MYR1.1B

25 mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25 mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparaison

Variation de prix

Anika Therapeutics Inc prévision

Objectif de Prix

By TipRanks

17.61% hausse

Prévisions sur 12 Mois

Moyen 17.5 USD 17.61%

Haut 18 USD

Bas 17 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

Achat

Maintien

Vente

Basé sur 2 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

159 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.